Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD63 | P08962 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 2/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24904153 | 0.90 | BRAF (0.42) | CD63SYKMAPTGAAALDH1A1 | |
| SCHEMBL20344872 | 0.88 | SYK (0.52) | CD63SYKMAPTGAAALDH1A1 | |
| SCHEMBL15540550 | 0.84 | NR4A1 (0.46) | MAPTGAAALDH1A1KDM4EHTT | |
| SCHEMBL30730929 | 0.82 | EML4 (0.43) | SYKMAPTGAAALDH1A1KDM4E | |
| SCHEMBL16848695 | 0.81 | CYP19A1 (0.44) | MAPTGAAALDH1A1MEN1POLB | |
| SCHEMBL30879147 | 0.81 | MAPT (0.54) | MAPTGAAALDH1A1KDM4EHTT | |
| SCHEMBL16851815 | 0.80 | CD63 (0.38) | CD63SYKMAPTGAAMEN1 | |
| SCHEMBL22164002 | 0.80 | BRAF (0.46) | SYKMAPTGAAALDH1A1KDM4E | |
| SCHEMBL30309444 | 0.80 | BRAF (0.46) | SYKMAPTGAAALDH1A1KDM4E | |
| SCHEMBL17630840 | 0.78 | MAP3K12 (0.41) | MAPTGAASMN1; SMN2TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | GILEAD SCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-9968601-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9931338-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170035755-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2017-02-09 | — | — | US | disclosed |
| US-20160375019-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-29 | — | — | US | disclosed |
| US-9504684-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160310490-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-10-27 | — | — | US | disclosed |
| US-9290505-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160058758-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20150175616-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158023-A1 | CRYSTALLINE SUCCINATE SALT OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[1,2-a]PYRAZIN-8-AMINE | SYK, LCK, LYN | CD63 3157/4885SYK 1/4885MAPT 1189/4885 |
| US-20170035755-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2809/4885SYK 1/4885MAPT 3043/4885 |
| US-20150175616-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2113/4885SYK 1/4885MAPT 2586/4885 |
| US-20160375019-A1 | TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE WITH SYK INHIBITORS | SYK, BTK, ZAP70 | CD63 1466/4885SYK 1/4885MAPT 4772/4885 |
| US-20160310490-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2113/4885SYK 1/4885MAPT 2586/4885 |
| US-20160058758-A1 | SYK INHIBITORS | SYK, BTK, LYN | CD63 2809/4885SYK 1/4885MAPT 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.